CAMP4 Therapeutics Corp. (CAMP)
4.26
-0.07
(-1.62%)
USD |
NASDAQ |
Nov 11, 12:20
CAMP4 Therapeutics Enterprise Value : 152.92M for Nov. 10, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 10, 2026 | 152.92M |
| November 09, 2026 | 175.52M |
| November 06, 2026 | 135.98M |
| November 05, 2026 | 114.64M |
| November 04, 2026 | 115.90M |
| November 03, 2026 | 121.55M |
| November 02, 2026 | 118.10M |
| October 30, 2026 | 129.70M |
| October 29, 2026 | 125.94M |
| October 28, 2026 | 110.25M |
| October 27, 2026 | 110.25M |
| October 26, 2026 | 82.64M |
| October 23, 2026 | 88.29M |
| October 22, 2026 | 93.93M |
| October 21, 2026 | 87.66M |
| October 20, 2026 | 79.50M |
| October 19, 2026 | 78.25M |
| October 16, 2026 | 80.13M |
| October 15, 2026 | 97.70M |
| October 14, 2026 | 96.44M |
| October 13, 2026 | 96.44M |
| October 12, 2026 | 110.88M |
| October 09, 2026 | 117.78M |
| October 08, 2026 | 113.39M |
| October 07, 2026 | 122.17M |
| Date | Value |
|---|---|
| October 06, 2026 | 129.70M |
| October 05, 2026 | 132.84M |
| October 02, 2026 | 132.21M |
| October 01, 2026 | 122.17M |
| September 30, 2026 | 134.72M |
| September 29, 2026 | 118.28M |
| September 28, 2026 | 115.16M |
| September 25, 2026 | 118.80M |
| September 24, 2026 | 114.64M |
| September 23, 2026 | 108.41M |
| September 22, 2026 | 130.74M |
| September 21, 2026 | 131.78M |
| September 18, 2026 | 135.41M |
| September 17, 2026 | 124.51M |
| September 16, 2026 | 115.68M |
| September 15, 2026 | 132.82M |
| September 14, 2026 | 135.93M |
| September 11, 2026 | 135.93M |
| September 10, 2026 | 140.61M |
| September 09, 2026 | 140.09M |
| September 08, 2026 | 143.72M |
| September 04, 2026 | 144.24M |
| September 03, 2026 | 148.40M |
| September 02, 2026 | 112.57M |
| September 01, 2026 | 112.05M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.254B |
| Alnylam Pharmaceuticals, Inc. | 19.71B |
| Anika Therapeutics, Inc. | 161.61M |
| Savara, Inc. | 911.95M |
| Vericel Corp. | 2.935B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.96M |
| Revenue (Quarterly) | 1.899M |
| Total Expenses (Quarterly) | 30.86M |
| EPS Diluted (Quarterly) | -0.3668 |
| Gross Profit Margin (Quarterly) | 72.46% |
| Profit Margin (Quarterly) | -1.52K% |
| Earnings Yield | -47.85% |
| Normalized Earnings Yield | -27.99 |